Compare Global X Defense Tech ETF (SHLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Defense Tech ETF trades at $59.87 (market cap $6.29B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.3× Global X Defense Tech ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SHLD | VRTX | |
|---|---|---|
Market Cap | $6.29B | $127.55B |
Volume | 1,133,252 | 1,487,944 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $557.96 |
52-Week Low | $58.20 | $407.37 |
Typical Hold Time | 44 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD, the Global X Defense Tech ETF, trades at $59.19, up 0.77% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower, while RSI levels suggest potential oversold conditions. The fund focuses on defense technology and cybersecurity, benefiting from rising global defense budgets, as highlighted by recent institutional buying and positive news flow on European rearmament efforts.
The outlook for SHLD is supported by geopolitical tailwinds and institutional accumulation, but near-term technical weakness and reliance on defense spending cycles pose risks. Investors gain exposure to innovative defense firms, yet must monitor budget approvals and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
